[go: up one dir, main page]

DE60040539D1 - VERWENDUNG VON FVIIa ODER EINES GEWEBEFAKTORAGONISTEN ZUR REGULIERUNG DER GENEXPRESSION UND ZELLMIGRATION ODER CHEMOTAXIS - Google Patents

VERWENDUNG VON FVIIa ODER EINES GEWEBEFAKTORAGONISTEN ZUR REGULIERUNG DER GENEXPRESSION UND ZELLMIGRATION ODER CHEMOTAXIS

Info

Publication number
DE60040539D1
DE60040539D1 DE60040539T DE60040539T DE60040539D1 DE 60040539 D1 DE60040539 D1 DE 60040539D1 DE 60040539 T DE60040539 T DE 60040539T DE 60040539 T DE60040539 T DE 60040539T DE 60040539 D1 DE60040539 D1 DE 60040539D1
Authority
DE
Germany
Prior art keywords
cell migration
fviia
chemotaxis
gene expression
tissue factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60040539T
Other languages
English (en)
Inventor
Mirella Ezban
Lars Christian Petersen
Agneta Siegbahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care AG filed Critical Novo Nordisk Health Care AG
Application granted granted Critical
Publication of DE60040539D1 publication Critical patent/DE60040539D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE60040539T 1999-07-14 2000-07-14 VERWENDUNG VON FVIIa ODER EINES GEWEBEFAKTORAGONISTEN ZUR REGULIERUNG DER GENEXPRESSION UND ZELLMIGRATION ODER CHEMOTAXIS Expired - Lifetime DE60040539D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199901023 1999-07-14
US14830099P 1999-08-11 1999-08-11
DKPA199901117 1999-08-12
PCT/DK2000/000401 WO2001005353A2 (en) 1999-07-14 2000-07-14 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS

Publications (1)

Publication Number Publication Date
DE60040539D1 true DE60040539D1 (de) 2008-11-27

Family

ID=27221063

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60040539T Expired - Lifetime DE60040539D1 (de) 1999-07-14 2000-07-14 VERWENDUNG VON FVIIa ODER EINES GEWEBEFAKTORAGONISTEN ZUR REGULIERUNG DER GENEXPRESSION UND ZELLMIGRATION ODER CHEMOTAXIS

Country Status (19)

Country Link
US (3) US20020193302A1 (de)
EP (1) EP1200116B1 (de)
JP (1) JP2003525028A (de)
KR (1) KR100821644B1 (de)
CN (1) CN100411684C (de)
AT (1) ATE411041T1 (de)
AU (1) AU5807500A (de)
BR (1) BR0012408A (de)
CA (1) CA2378249A1 (de)
CZ (1) CZ200240A3 (de)
DE (1) DE60040539D1 (de)
ES (1) ES2316372T3 (de)
HU (1) HUP0302052A3 (de)
IL (1) IL147294A0 (de)
MX (1) MXPA02000468A (de)
NO (1) NO20020130L (de)
PL (1) PL353035A1 (de)
RU (1) RU2268744C2 (de)
WO (1) WO2001005353A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271365A1 (en) * 2000-06-21 2002-01-02 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
DE10238429A1 (de) 2002-03-19 2003-10-30 Aventis Behring Gmbh Intellect Marburg I Mutante der Faktor VII aktivierenden Protease (FSAP) als Risikofaktor für Atherosklerose
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
EP1443956A2 (de) * 2001-11-02 2004-08-11 Novo Nordisk Health Care AG Verwendung des gewebefaktor-agonisten oder gewebefaktor-antagonisten zur behandlung von erkrankungen im zusammenhang mit apoptose
EP1471818A4 (de) * 2002-02-04 2007-03-28 Millennium Pharm Inc Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen unter verwendung von 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 oder 13249 molekülen
CA2534996A1 (en) * 2003-08-06 2005-05-06 Hans Prydz The use of sirna silencing in the prevention of metastasis
KR20070012715A (ko) * 2004-04-16 2007-01-26 더 스크립스 리서치 인스티튜트 혈관신생 조절방법
US20100028358A1 (en) * 2005-11-07 2010-02-04 Wolfram Ruf Compositions and Methods for Controlling Tissue Factor Signaling Specificity
WO2008103812A1 (en) * 2007-02-21 2008-08-28 Yale University Compositions and methods for diagnosing and treating endometriosis
BRPI1100062A2 (pt) 2011-07-01 2016-08-02 Shiseido Co Ltd promotor de produção de fator bb de crescimento derivado de plaqueta, e acelerador de produção de célula-tronco mesenquimal, estabilizante de célula-tronco e regenerador dérmico que compreende o mesmo
CN109381478A (zh) * 2018-10-31 2019-02-26 青岛大学附属医院 一种miRNA在制备抑制新生血管生成和抑制VEGF-A因子表达的试剂中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006855A1 (en) 1991-10-11 1993-04-15 Novo Nordisk A/S Hemostatic composition for local hemostasis
DE19538715A1 (de) * 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
CN1263852C (zh) 1996-03-15 2006-07-12 穆尼恩公司 胞外基质信号分子
WO1998058661A1 (en) 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
US20030040481A1 (en) * 1997-07-18 2003-02-27 Lars Kongsbak Methods for modifying cell motility using a factor VIIa antagonist
DE69841434D1 (de) * 1997-07-18 2010-02-25 Novo Nordisk Healthcare Ag VERWENDUNG VON FVIIa ODER FVIIAi ZUR BEHANDLUNG VON ENDOTHELIALER FEHLFUNKTION BZW ZUR INHIBIERUNG DER ANGIOGENESE
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
HUP0401124A3 (en) 2001-03-22 2006-01-30 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
KR20040094288A (ko) 2001-05-02 2004-11-09 노보 노르디스크 에이/에스 Ａｒｄｓ의 치료에 있어 변형된 ｆⅶ
HUP0400976A3 (en) 2001-07-20 2006-01-30 Novo Nordisk Healthcare Ag Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides
AU2002340779B2 (en) 2001-11-09 2007-08-02 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
EP1446147A1 (de) 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmazeutische zusammensetzung, die faktor vii polypeptide und tranexamsäure enthält
EP1446148A1 (de) 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmazeutische zusammensetzung mit einem faktor-vii-polypeptid und epsilon-aminocapronsäure
EP1446155A1 (de) 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmazeutische zusammensetzung mit faktor-vii-polypeptiden und aprotinin-polypeptiden

Also Published As

Publication number Publication date
CZ200240A3 (cs) 2003-04-16
US20020193302A1 (en) 2002-12-19
RU2268744C2 (ru) 2006-01-27
CA2378249A1 (en) 2001-01-25
US7829529B2 (en) 2010-11-09
ES2316372T3 (es) 2009-04-16
NO20020130D0 (no) 2002-01-11
IL147294A0 (en) 2002-08-14
PL353035A1 (en) 2003-10-06
KR20020025194A (ko) 2002-04-03
MXPA02000468A (es) 2008-10-06
AU5807500A (en) 2001-02-05
HUP0302052A3 (en) 2005-12-28
ATE411041T1 (de) 2008-10-15
EP1200116B1 (de) 2008-10-15
US20050239708A1 (en) 2005-10-27
NO20020130L (no) 2002-03-13
CN100411684C (zh) 2008-08-20
HUP0302052A2 (hu) 2003-09-29
EP1200116A2 (de) 2002-05-02
US20090036378A1 (en) 2009-02-05
CN1460024A (zh) 2003-12-03
BR0012408A (pt) 2002-03-12
WO2001005353A2 (en) 2001-01-25
WO2001005353A3 (en) 2001-07-19
KR100821644B1 (ko) 2008-04-11
JP2003525028A (ja) 2003-08-26

Similar Documents

Publication Publication Date Title
DE60040539D1 (de) VERWENDUNG VON FVIIa ODER EINES GEWEBEFAKTORAGONISTEN ZUR REGULIERUNG DER GENEXPRESSION UND ZELLMIGRATION ODER CHEMOTAXIS
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69422726D1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
ATE414556T1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
DE59601624D1 (de) Verwendung von 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
DE602006020775D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
ATE275919T1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
DE69738887D1 (de) Tumor necrosis factor rezeptor abspaltendes enzym, dessen zubereitungen und verwendungen
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
BR0315344A (pt) Métodos para prever edema como um efeito colateral do tratamento com drogas
ATE353662T1 (de) Verwendung von tetrahydrocurcuminoiden zur regulation von physiologischen und pathologischen fällen in der haut und mucosa
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE420636T1 (de) Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen
ATE257384T1 (de) Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen
DE50103012D1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition